Mepsevii™ (vestronidase alfa-vjbk) – New orphan drug approval
November 15, 2017 – The FDA announced the approval of Ultragenyx’s Mepsevii (vestronidase alfa-vjbk), in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
Download PDF
